BH.IMMUN&BIO | AJANTA PHARMA | BH.IMMUN&BIO/ AJANTA PHARMA |
|||
---|---|---|---|---|---|
P/E (TTM) | x | -8.3 | 36.5 | - | View Chart |
P/BV | x | 1.6 | 7.9 | 20.6% | View Chart |
Dividend Yield | % | 0.0 | 0.3 | - |
BH.IMMUN&BIO AJANTA PHARMA |
EQUITY SHARE DATA | |||||
---|---|---|---|---|---|
BH.IMMUN&BIO Mar-23 |
AJANTA PHARMA Mar-23 |
BH.IMMUN&BIO/ AJANTA PHARMA |
5-Yr Chart Click to enlarge
|
||
High | Rs | 52 | 1,426 | 3.6% | |
Low | Rs | 21 | 1,062 | 1.9% | |
Sales per share (Unadj.) | Rs | 10.3 | 297.2 | 3.5% | |
Earnings per share (Unadj.) | Rs | -3.9 | 46.7 | -8.3% | |
Cash flow per share (Unadj.) | Rs | -3.8 | 57.1 | -6.7% | |
Dividends per share (Unadj.) | Rs | 0 | 7.00 | 0.0% | |
Avg Dividend yield | % | 0 | 0.6 | 0.0% | |
Book value per share (Unadj.) | Rs | 20.4 | 269.1 | 7.6% | |
Shares outstanding (eoy) | m | 43.18 | 125.91 | 34.3% | |
Bonus / Rights / Conversions | 0 | 0 | - | ||
Price / Sales ratio | x | 3.5 | 4.2 | 83.6% | |
Avg P/E ratio | x | -9.4 | 26.6 | -35.2% | |
P/CF ratio (eoy) | x | -9.5 | 21.8 | -43.6% | |
Price / Book Value ratio | x | 1.8 | 4.6 | 38.3% | |
Dividend payout | % | 0 | 15.0 | -0.0% | |
Avg Mkt Cap | Rs m | 1,561 | 156,638 | 1.0% | |
No. of employees | `000 | NA | NA | - | |
Total wages/salary | Rs m | 151 | 7,851 | 1.9% | |
Avg. sales/employee | Rs Th | 0 | 0 | - | |
Avg. wages/employee | Rs Th | 0 | 0 | - | |
Avg. net profit/employee | Rs Th | 0 | 0 | - |
INCOME DATA | |||||
---|---|---|---|---|---|
Net Sales | Rs m | 446 | 37,426 | 1.2% | |
Other income | Rs m | 11 | 986 | 1.1% | |
Total revenues | Rs m | 457 | 38,413 | 1.2% | |
Gross profit | Rs m | -161 | 7,833 | -2.1% | |
Depreciation | Rs m | 2 | 1,308 | 0.2% | |
Interest | Rs m | 71 | 58 | 120.9% | |
Profit before tax | Rs m | -223 | 7,453 | -3.0% | |
Minority Interest | Rs m | 0 | 0 | - | |
Prior Period Items | Rs m | 0 | 0 | - | |
Extraordinary Inc (Exp) | Rs m | 0 | 0 | - | |
Tax | Rs m | -56 | 1,573 | -3.6% | |
Profit after tax | Rs m | -166 | 5,880 | -2.8% | |
Gross profit margin | % | -36.0 | 20.9 | -172.1% | |
Effective tax rate | % | 25.3 | 21.1 | 119.8% | |
Net profit margin | % | -37.3 | 15.7 | -237.4% |
BALANCE SHEET DATA | |||||
---|---|---|---|---|---|
Current assets | Rs m | 358 | 28,252 | 1.3% | |
Current liabilities | Rs m | 940 | 11,393 | 8.3% | |
Net working cap to sales | % | -130.6 | 45.0 | -289.8% | |
Current ratio | x | 0.4 | 2.5 | 15.4% | |
Inventory Days | Days | 85 | 66 | 129.8% | |
Debtors Days | Days | 1,135 | 10 | 11,015.0% | |
Net fixed assets | Rs m | 1,262 | 18,707 | 6.7% | |
Share capital | Rs m | 432 | 253 | 170.9% | |
"Free" reserves | Rs m | 450 | 33,624 | 1.3% | |
Net worth | Rs m | 882 | 33,877 | 2.6% | |
Long term debt | Rs m | 0 | 13 | 0.0% | |
Total assets | Rs m | 1,620 | 47,047 | 3.4% | |
Interest coverage | x | -2.2 | 128.6 | -1.7% | |
Debt to equity ratio | x | 0 | 0 | 0.0% | |
Sales to assets ratio | x | 0.3 | 0.8 | 34.6% | |
Return on assets | % | -5.9 | 12.6 | -46.8% | |
Return on equity | % | -18.9 | 17.4 | -108.7% | |
Return on capital | % | -17.2 | 22.2 | -77.8% | |
Exports to sales | % | 0 | 59.9 | 0.0% | |
Imports to sales | % | 14.5 | 11.5 | 126.1% | |
Exports (fob) | Rs m | NA | 22,420 | 0.0% | |
Imports (cif) | Rs m | 65 | 4,293 | 1.5% | |
Fx inflow | Rs m | 0 | 22,420 | 0.0% | |
Fx outflow | Rs m | 65 | 4,293 | 1.5% | |
Net fx | Rs m | -65 | 18,127 | -0.4% |
CASH FLOW | |||||
---|---|---|---|---|---|
From Operations | Rs m | 109 | 7,918 | 1.4% | |
From Investments | Rs m | 5 | -5,596 | -0.1% | |
From Financial Activity | Rs m | -147 | -1,079 | 13.6% | |
Net Cashflow | Rs m | -34 | 1,243 | -2.7% |
Indian Promoters | % | 59.3 | 66.2 | 89.5% | |
Foreign collaborators | % | 0.0 | 0.0 | - | |
Indian inst/Mut Fund | % | 0.0 | 26.0 | - | |
FIIs | % | 0.0 | 8.5 | - | |
ADR/GDR | % | 0.0 | 0.0 | - | |
Free float | % | 40.8 | 33.8 | 120.6% | |
Shareholders | 35,313 | 55,488 | 63.6% | ||
Pledged promoter(s) holding | % | 0.0 | 12.3 | - |
Compare BH.IMMUN&BIO With: DIVIS LABORATORIES CIPLA SUN PHARMA DR. REDDYS LAB ZYDUS LIFESCIENCES
No comparison is complete without understanding how the stock prices have performed over a period of time.
Here's a brief comparison:
Period | BH.IMMUN&BIO | AJANTA PHARMA | S&P BSE HEALTHCARE |
---|---|---|---|
1-Day | 12.46% | -0.21% | 1.03% |
1-Month | 9.97% | -3.96% | 1.10% |
1-Year | 37.99% | 65.86% | 53.75% |
3-Year CAGR | -8.02% | 21.10% | 14.67% |
5-Year CAGR | 31.91% | 25.53% | 19.26% |
* Compound Annual Growth Rate
Here are more details on the BH.IMMUN&BIO share price and the AJANTA PHARMA share price.
Moving on to shareholding structures...
The promoters of BH.IMMUN&BIO hold a 59.3% stake in the company. In case of AJANTA PHARMA the stake stands at 66.2%.
To review how promoter stakes have changed over time, and how much of the promoter stake is pledged, please see the shareholding pattern of BH.IMMUN&BIO and the shareholding pattern of AJANTA PHARMA.
Finally, a word on dividends...
In the most recent financial year, BH.IMMUN&BIO paid a dividend of Rs 0.0 per share. This amounted to a Dividend Payout ratio of -0.0%.
AJANTA PHARMA paid Rs 7.0, and its dividend payout ratio stood at 15.0%.
You may visit here to review the dividend history of BH.IMMUN&BIO, and the dividend history of AJANTA PHARMA.
For a sector overview, read our pharmaceuticals sector report.
After opening the day on high, Indian share markets continued the momentum as the session progressed and ended the higher.